Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label study of BI 765063 alone and with BI 754091 in Japanese patients with advanced solid tumors
jRCT2031200355Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 765063 and ezabenlimab in Nonhematologic neoplasms (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum tolerated dose (MTD) and Number of patients with dose-limiting toxicities (DLTs) in MTD evaluation period. Started Dec 2020; status: active, not recruiting.
02
Drugs
BI 765063ezabenlimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031200355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200355.